DSIP vs Humanin
Both DSIP and Humanin are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
DSIP
Evidence CDelta Sleep-Inducing Peptide
A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.
View full DSIP profile →Humanin
Evidence BHumanin (HN)
A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.
View full Humanin profile →Side-by-Side
| Attribute | DSIP | Humanin |
|---|---|---|
| Evidence Grade | C | B |
| FDA Status | Not FDA-approved — research compound | Not FDA-approved — mitochondrial-derived peptide research compound |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | Research range: 0.5–1 mg subcutaneous (rare clinical use) |
| Clinics Indexed | 38 | 5 |
| Categories | sleep, neuroprotection | mitochondrial, longevity, neuroprotection |
Key reported benefits — DSIP
- ✓Slow-wave-sleep signals (preclinical)
- ✓Stress/cortisol modulation
- ✓Possible analgesic effect
Key reported benefits — Humanin
- ✓Cytoprotection
- ✓Anti-amyloid effects
- ✓Insulin sensitization
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.